Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01125813 |
Recruitment Status :
Completed
First Posted : May 18, 2010
Results First Posted : April 22, 2013
Last Update Posted : September 11, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Severe Hemophilia A | Biological: recombinant Factor VIII | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Hemophilia A |
Study Start Date : | June 2010 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: human cl-rhFVIII |
Biological: recombinant Factor VIII
intravenous infusion of factor FVIII every other day.
Other Name: human-cl rhFVIII |
- Efficacy Assessment After a Total of at Least 50 EDs Per Subject at the End of the Study at 6 Months [ Time Frame: At least 50 Exposure Days and at least 6 months ]Frequency of spontaneous breakthrough bleeds/months under prophylactic treatment.
- Efficacy of Treating Bleeding Episodes [ Time Frame: After each bleeding episode, up to 6 month ]
At the end of a bleeding episode, efficacy was assessed as:
- Excellent: Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single infusion
- Good: Definite pain relief and/or improvement in signs of bleeding within approximately 8-12 hours after an infusion requiring up to 2 infusions for complete resolution
- Moderate: Probable or slight beneficial effect within approximately 12 hours after the first infusion requiring more than two infusions for complete resolution
- None: No improvement within 12 hours, or worsening of symptoms, requiring more than 2 infusions for complete resolution Efficacy was rated
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Severe hemophilia A ((FVIII:C <= 1%)
- Male subjects >= 12 years of age
- Previously treated with FVIII concentrate, at least 50 EDs
- Immunocompetent (CD4+ count > 200/ul)
- Negative for anti- HIV; if positive, viral load < 200 particles/u; or <400,000 copies/mL
Exclusion Criteria:
- Other coagulation disorder than hemophilia A
- Present of past FVIII inhibitor activity (.= 0.6 BU)
- Severe liver and kidney disease
- Receiving of scheduled to receive immuno-modulating drugs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01125813
Austria | |
Medizinische Universitaet Wien | |
Wien, Austria, 1090 | |
Bulgaria | |
Haematological Hospital Joan Pavel | |
Sofia, Bulgaria, 1233 | |
Germany | |
Werlhof Institut fuer Haemostaseologie GmbH | |
Hannover, Niedersachsen, Germany, 30159 | |
Universitaetsklinikum | |
Bonn, Germany | |
Universitaetsklinikum Hamburg-Eppendorf | |
Hamburg, Germany, 20246 | |
SRH Kurpfalzkrankenhaus Heidelberg | |
Heidelberg, Germany, 69123 | |
United Kingdom | |
Basingstoke & North Hampshire NHS Foundation Trust | |
Basingstoke, United Kingdom, RG24 9NA | |
University Hospital of Wales | |
Cardiff, United Kingdom | |
Royal Free Hospital | |
London, United Kingdom | |
Manchester Royal Infirmary | |
Manchester, United Kingdom | |
Royal Hallamshire Hospital | |
Sheffield, United Kingdom |
Principal Investigator: | Johannes Oldenburg, Prof. | Universitaetsklinikum Bonn |
Responsible Party: | Octapharma |
ClinicalTrials.gov Identifier: | NCT01125813 |
Other Study ID Numbers: |
GENA-08 |
First Posted: | May 18, 2010 Key Record Dates |
Results First Posted: | April 22, 2013 |
Last Update Posted: | September 11, 2017 |
Last Verified: | August 2017 |
Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders |
Hemorrhagic Disorders Genetic Diseases, Inborn Factor VIII Coagulants |